GlassScriptPhysician profile
Nitika Malhotra
NPI 1164742144
$11,423.48
in general payments reported to CMS, 2019-2025
42 companies · $647 in 2025
The $647 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,545 · 2020: $1,922 · 2021: $2,251 · 2022: $2,496 · 2023: $1,952 · 2024: $611 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,209.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $2,073.65 | 2019-2024 | Afrezza |
| Novo Nordisk INC | $1,341.54 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Sanofi-Aventis U.S. LLC | $824.76 | 2019-2023 | |
| Radius Health, INC. | $717.49 | 2019-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $641.94 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Abbott Laboratories | $641.65 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $627.65 | 2019-2023 | Jardiance, Tradjenta |
| Lilly USA, LLC | $565.16 | 2019-2023 | Jardiance, Mounjaro, Lyumjev |
| Corcept Therapeutics | $502.96 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $465.44 | 2019-2022 | |
| Amgen INC. | $379.79 | 2019-2025 | Prolia, Evenity, Tepezza |
| Dexcom, INC. | $372.66 | 2019-2023 | Dexcom G6 Transmitter |
| Insulet Corporation | $309.88 | 2019-2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $231.96 | 2020-2025 | Unithroid |
| Ascensia Diabetes Care US INC. | $223.94 | 2022-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitika Malhotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.